The quarter's performance was marred by a sharp contraction in sales, which fell 14.30% year-on-year to ₹474.34 crores—the lowest quarterly revenue in the past seven quarters. More alarmingly, operating profit before depreciation, interest, tax, and other income (PBDIT excluding OI) plummeted to just ₹19.72 crores, translating to an operating margin of merely 4.16%, down sharply from 11.83% in Q4 FY25. This represents the weakest operational performance in recent memory, signalling severe pressure on pricing power and cost structures.
The company's ability to generate meaningful operating profits has been severely compromised, with the operating profit-to-interest coverage ratio dropping to a precarious 0.96 times—the lowest on record. This deterioration underscores the strain of elevated interest costs (₹20.48 crores in Q4 FY26) on an already fragile earnings base. Adding to the distress, profit before tax stood at just ₹7.15 crores, propped up significantly by other income of ₹37.24 crores, which constituted a staggering 520.84% of PBT—a clear red flag indicating the company's core operations are failing to sustain profitability independently.
| Quarter | Revenue (₹ Cr) | Net Profit (₹ Cr) | Operating Margin (%) | PAT Margin (%) |
|---|---|---|---|---|
| Mar'26 | 474.34 | 8.03 | 4.16% | 1.69% |
| Dec'25 | 508.74 | -3.53 | 7.42% | -0.69% |
| Sep'25 | 577.26 | 11.55 | 9.03% | 2.00% |
| Jun'25 | 613.62 | 12.68 | 10.90% | 2.07% |
| Mar'25 | 553.46 | 19.82 | 11.83% | 3.58% |
| Dec'24 | 568.51 | -4.39 | 7.18% | -0.77% |
| Sep'24 | 543.89 | -9.27 | 5.62% | -1.70% |
Financial Performance: A Deepening Crisis
Meghmani Organics' financial performance in Q4 FY26 reflects a company in distress. Net sales of ₹474.34 crores marked a sequential decline of 6.76% from Q3 FY26 and a year-on-year contraction of 14.30%, indicating weakening demand and competitive pressures in the agrochemicals market. The company's gross profit margin stood at 7.69% in Q4 FY26, a modest improvement from the prior quarter's 6.77% but still significantly below the 10.85% achieved in Q4 FY25, reflecting ongoing challenges in raw material costs and pricing dynamics.
The most concerning aspect of the quarter was the collapse in operating margins. Operating profit excluding other income fell to ₹19.72 crores, yielding a margin of just 4.16%—the lowest in at least seven quarters. This compares unfavourably to the 11.83% margin in Q4 FY25 and even the 7.42% in Q3 FY26. The sharp margin compression suggests the company is struggling with cost inflation, pricing pressures, or both, and is unable to pass on costs to customers in a competitive market environment.
Net profit after tax of ₹8.03 crores translated to a PAT margin of 1.69%, down from 3.58% in Q4 FY25. The company's quarterly PAT has fallen 20.70% compared to the previous four-quarter average, highlighting a structural decline in profitability. The tax expense anomaly in Q4 FY26—a negative ₹0.89 crores—further complicates the earnings picture, suggesting tax adjustments or credits that mask the underlying weakness in pre-tax profitability.
Operational Challenges: Weak Capital Efficiency and Margin Erosion
The company's operational efficiency metrics paint a troubling picture. Return on equity (ROE) averaged just 6.03% over recent periods—well below the industry standard for capital-intensive chemical businesses and significantly trailing peers like Bharat Rasayan (15.82%) and India Pesticides (13.27%). The latest ROE of 2.58% is particularly weak, indicating that the company is generating minimal returns on shareholder capital. Return on capital employed (ROCE) averaged 7.62%, with the latest figure at 4.55%, reflecting poor asset utilisation and deteriorating profitability.
The company's balance sheet has shown signs of strain. Long-term debt stood at ₹283.29 crores as of March 2025, down from ₹383.13 crores in March 2024, indicating some deleveraging efforts. However, the debt-to-EBITDA ratio of 0.93 and net debt-to-equity ratio of 0.52 remain elevated given the weak earnings trajectory. More concerning is the operating profit-to-interest coverage ratio, which plummeted to 0.96 times in Q4 FY26—the lowest on record—meaning the company barely generated enough operating profit to cover its interest obligations. This raises serious questions about financial sustainability if profitability does not improve swiftly.
Fixed assets increased significantly to ₹1,574.90 crores in March 2025 from ₹1,151.66 crores the prior year, suggesting substantial capital expenditure. However, this expansion has not translated into improved operational performance or margins, indicating potential underutilisation of new capacity or delays in ramping up production. The sales-to-capital-employed ratio of 0.99 suggests that the company is generating less than one rupee of sales for every rupee of capital deployed—a sign of inefficient capital allocation.
Critical Red Flag: Over-Reliance on Non-Operating Income
Other income of ₹37.24 crores in Q4 FY26 constituted 520.84% of profit before tax, meaning the company's core operations generated a loss before other income. This heavy dependence on non-operating income—which can be volatile and non-recurring—raises serious concerns about the sustainability of reported profits. Profit before tax less other income stood at a negative ₹30.09 crores, the lowest figure on record, underscoring the severity of operational underperformance.
Industry Context: Agrochemicals Sector Under Pressure
The pesticides and agrochemicals sector has faced headwinds over the past year, with the Pesticides & Agrochemicals index declining 13.70% over the 12-month period. Meghmani Organics has significantly underperformed this benchmark, posting a loss of 33.31%—an underperformance of 19.61 percentage points. This suggests company-specific challenges beyond broader sectoral trends, including potential market share losses, pricing pressures, or operational inefficiencies.
The agrochemicals industry is characterised by cyclical demand patterns, regulatory pressures, raw material cost volatility, and intense competition from both domestic and international players. Generic agrochemical pricing has been under pressure globally, and Indian manufacturers have faced challenges in export markets due to oversupply and destocking by global distributors. Meghmani Organics' pigment and agrochemicals business appears particularly vulnerable to these dynamics, with the company unable to sustain margins in a challenging pricing environment.
Competitors with stronger product portfolios, better operational efficiency, and diversified revenue streams have fared better. The company's inability to maintain pricing power or reduce costs effectively has resulted in margin compression that is more severe than many peers, suggesting structural weaknesses in its business model or product mix.
| Company | P/E (TTM) | P/BV | ROE (%) | Debt to Equity |
|---|---|---|---|---|
| Meghmani Organics | 33.09 | 0.87 | 6.03% | 0.52 |
| Bharat Rasayan | 16.62 | 1.98 | 15.82% | -0.16 |
| Insecticides India | 14.49 | 1.71 | 10.95% | 0.18 |
| India Pesticides | 17.58 | 2.04 | 13.27% | -0.08 |
| GSP Crop Science | 26.58 | 4.77 | 0.00% | 0.00 |
| Astec Lifesciences | NA (Loss Making) | 3.77 | 5.75% | 1.12 |
Meghmani Organics trades at a P/E ratio of 33.09x—substantially higher than peers like Bharat Rasayan (16.62x) and Insecticides India (14.49x)—despite delivering significantly lower ROE of 6.03% compared to peers averaging around 10-15%. The company's price-to-book ratio of 0.87x is the lowest in the peer group, reflecting market scepticism about asset quality and future earnings potential. This valuation disconnect—high P/E but low P/BV—suggests the market is pricing in minimal earnings growth and potential further deterioration.
Valuation Analysis: Overvalued Despite Price Decline
At the current price of ₹52.37, Meghmani Organics trades at a P/E ratio of 33.09x based on trailing twelve-month earnings—a premium that appears unjustified given the company's weak fundamentals and deteriorating financial trends. The price-to-book ratio of 0.87x suggests the market values the company below its stated book value of ₹59.58 per share, reflecting concerns about asset quality, future profitability, or both.
The company's EV/EBITDA multiple of 9.63x and EV/EBIT of 20.76x appear reasonable on the surface, but these metrics are distorted by the inclusion of volatile other income and do not reflect the underlying weakness in core operating profitability. The EV/Sales ratio of 0.95x indicates the market values the company at slightly below one times revenue, which is low but appropriate given the poor margin profile and negative earnings trajectory.
The PEG ratio of 0.18x might suggest undervaluation, but this metric is misleading given the company's negative five-year EBIT growth rate of -17.31%. In reality, the company is destroying value rather than growing, making traditional growth-based valuation metrics inappropriate. The valuation grade has fluctuated between "Fair" and "Attractive" over the past year, but the current "Fair" assessment appears generous given the fundamental deterioration.
Shareholding: Institutional Exodus Underway
The shareholding pattern reveals a concerning trend of institutional disinterest and gradual promoter stake reduction. Promoter holding stood at 48.95% as of March 2026, down marginally from 48.98% in December 2025 and 49.41% in March 2025. Whilst the decline is modest, the trend suggests a lack of conviction from the promoter group, though positively, there is no pledging of promoter shares.
Foreign institutional investor (FII) holding has remained negligible at 1.34%, with minimal sequential change. More telling is the complete absence of mutual fund holdings (0.00%) and insurance company holdings (0.00%), indicating that domestic institutional investors have no appetite for the stock. Other domestic institutional investor (DII) holdings have declined sharply from 0.53% in March 2025 to just 0.04% in March 2026, reflecting institutional selling pressure.
Non-institutional holdings (retail and other investors) have increased to 49.66% from 48.25% a year ago, suggesting retail investors are holding or accumulating shares even as institutions exit. This inverse relationship—institutions selling whilst retail investors hold—is typically a bearish signal, as institutional investors generally have better access to information and more rigorous analytical frameworks.
| Category | Mar'26 | Dec'25 | Sep'25 | QoQ Change |
|---|---|---|---|---|
| Promoter | 48.95% | 48.98% | 48.98% | -0.03% |
| FII | 1.34% | 1.33% | 1.48% | +0.01% |
| Mutual Funds | 0.00% | 0.00% | 0.00% | 0.00% |
| Insurance | 0.00% | 0.00% | 0.00% | 0.00% |
| Other DII | 0.04% | 0.04% | 0.04% | 0.00% |
| Non-Institutional | 49.66% | 49.65% | 49.50% | +0.01% |
Stock Performance: Severe Underperformance Across All Timeframes
Meghmani Organics has delivered dismal returns across virtually all timeframes, significantly underperforming both the Sensex and its sectoral peers. Over the past year, the stock has declined 33.31% compared to the Sensex's fall of 7.29%, generating a negative alpha of 26.02 percentage points. The underperformance is even more stark over longer periods: the stock is down 36.99% over two years (vs. Sensex +3.14%), down 37.24% over three years (vs. Sensex +21.56%), and down a staggering 54.60% over four years (vs. Sensex +42.82%).
Short-term performance has been equally volatile and disappointing. The stock fell 12.51% over the past week compared to the Sensex's decline of 3.14%, and dropped 3.25% on the most recent trading day against a Sensex gain of 1.06%. The only positive note is the one-month return of 8.29%, but this appears to be a technical bounce rather than a sustained recovery, as the three-month and six-month returns remain deeply negative at -3.47% and -27.21% respectively.
The stock's beta of 1.72 indicates it is significantly more volatile than the broader market, amplifying both gains and losses. However, given the consistently negative returns, this high beta has worked against investors, magnifying losses during market downturns. The risk-adjusted return of -0.75 over one year, combined with high volatility of 44.18%, places the stock firmly in the "high risk, low return" category—the worst quadrant for any investment.
| Period | Stock Return | Sensex Return | Alpha |
|---|---|---|---|
| 1 Day | -3.25% | +1.06% | -4.31% |
| 1 Week | -12.51% | -3.14% | -9.37% |
| 1 Month | +8.29% | -1.89% | +10.18% |
| 3 Months | -3.47% | -8.75% | +5.28% |
| 6 Months | -27.21% | -10.84% | -16.37% |
| 1 Year | -33.31% | -7.29% | -26.02% |
| 2 Years | -36.99% | +3.14% | -40.13% |
| 3 Years | -37.24% | +21.56% | -58.80% |
Investment Thesis: Multiple Red Flags Dominate
The investment case for Meghmani Organics is overwhelmingly negative across all critical parameters. The company's proprietary Mojo Score stands at a dismal 23 out of 100, firmly in the "Strong Sell" category (0-30 range), and has declined from 37 in recent months. This deterioration reflects worsening fundamentals across valuation, quality, financial trends, and technical indicators.
The quality assessment is "Below Average," with the company exhibiting weak long-term fundamental strength characterised by a negative five-year EBIT CAGR of -17.31%. Whilst the company benefits from zero promoter pledging and a relatively manageable debt burden, these positives are overwhelmed by poor capital efficiency (ROE of 6.03%, ROCE of 7.62%), weak interest coverage, and persistently low institutional holdings of just 1.39%.
The financial trend is classified as "Negative," driven by multiple concerning factors: operating profit-to-interest coverage at a precarious 0.96 times, quarterly PAT down 20.70% versus the prior four-quarter average, operating margin at a seven-quarter low of 4.16%, and non-operating income comprising over 500% of PBT. These metrics collectively indicate a company struggling to generate sustainable profits from core operations.
Technical indicators paint an equally bearish picture, with the stock in a "Mildly Bearish" trend since May 11, 2026. The stock trades below all key moving averages (5-day, 20-day, 50-day, 100-day, and 200-day), and technical indicators including MACD (monthly bearish), Bollinger Bands (monthly mildly bearish), and KST (monthly bearish) all suggest further downside risk. The stock sits 50.61% below its 52-week high of ₹106.03, with immediate support at the 52-week low of ₹36.41—a level that could be tested if operational trends do not improve.
Key Strengths & Risk Factors
KEY STRENGTHS
- Zero Promoter Pledging: No shares pledged by promoters, indicating no immediate financial distress at the promoter level.
- Deleveraging Efforts: Long-term debt reduced from ₹383.13 crores (Mar'24) to ₹283.29 crores (Mar'25), showing debt reduction initiatives.
- Diversified Product Portfolio: Presence in both pigments and agrochemicals provides some business diversification, though neither segment is performing well currently.
- Established Market Presence: Company has been operating in the chemicals space with established customer relationships and distribution networks.
- Low P/BV Ratio: Trading at 0.87x book value suggests potential asset value, though this may reflect concerns about asset quality.
KEY CONCERNS
- Collapsing Margins: Operating margin at 4.16% (lowest in 7 quarters) down from 11.83% in Q4 FY25, indicating severe pricing pressure or cost inflation.
- Weak Capital Efficiency: ROE of 6.03% and ROCE of 7.62% are significantly below industry standards and peer performance.
- Over-Reliance on Other Income: Other income constitutes 520.84% of PBT, meaning core operations are loss-making before non-operating income.
- Poor Interest Coverage: Operating profit-to-interest ratio of 0.96x (lowest on record) raises serious concerns about debt servicing capability.
- Negative Growth Trajectory: Five-year EBIT CAGR of -17.31% and declining quarterly revenues indicate structural business challenges.
- Institutional Exodus: Zero mutual fund holdings, negligible FII holdings (1.34%), and declining DII holdings signal lack of institutional confidence.
- Severe Stock Underperformance: Down 33.31% over one year vs. Sensex -7.29%, with negative alpha of 26.02 percentage points.
Outlook: What to Monitor
POSITIVE CATALYSTS
- Margin Recovery: Any signs of operating margin improvement above 8-10% would indicate pricing power restoration or cost control success.
- Revenue Stabilisation: Quarterly revenues stabilising above ₹550 crores and showing sequential growth would signal demand recovery.
- Interest Coverage Improvement: Operating profit-to-interest ratio moving above 2.0x would ease financial sustainability concerns.
- Institutional Interest: Meaningful accumulation by mutual funds or FIIs would signal improving confidence in the turnaround story.
- Capacity Utilisation: Improved utilisation of recent capex investments translating to better sales-to-capital-employed ratios.
RED FLAGS TO WATCH
- Further Margin Compression: Operating margins falling below 4% would indicate deepening operational crisis.
- Continued Revenue Decline: Quarterly revenues falling below ₹450 crores would signal accelerating business deterioration.
- Rising Debt Levels: Any increase in debt whilst profitability remains weak would raise solvency concerns.
- Promoter Stake Reduction: Accelerated selling by promoters would signal loss of confidence in the business.
- Technical Breakdown: Stock breaking below ₹36.41 (52-week low) would likely trigger further selling pressure.
The Verdict: Exit Recommended
Score: 23/100
For Fresh Investors: Avoid completely. The company exhibits multiple red flags including collapsing margins, weak capital efficiency, poor interest coverage, and negative growth trajectory. The stock trades at an unjustified premium (P/E 33.09x) despite delivering returns well below peers and benchmark indices. There are far better opportunities in the agrochemicals space with stronger fundamentals and clearer growth visibility.
For Existing Holders: Consider exiting the position at current levels or on any relief rallies. The deteriorating financial trend, negative quarterly momentum, and bearish technical setup suggest further downside risk. With the stock already down 33.31% over one year and 50.61% from its 52-week high, the risk-reward profile remains highly unfavourable. The company needs to demonstrate sustained margin recovery and revenue growth before reconsidering—neither appears imminent based on current trends.
Fair Value Estimate: ₹40-45 (23.57% downside from current price of ₹52.37). This valuation assumes operating margins stabilise around 6-7% and revenue decline moderates, both of which are optimistic scenarios given current trajectory.
Note- ROCE= (EBIT - Other income)/(Capital Employed - Cash - Current Investments)
⚠️ Investment Disclaimer
This article is for educational and informational purposes only and should not be construed as financial advice. Investors should conduct their own due diligence, consider their risk tolerance and investment objectives, and consult with a qualified financial advisor before making any investment decisions.
